Alectinib‐resistant ALK mutations have not been reported in patients with ALK+ALCL, and several patients have been reported to have survived more than 1 year with continuous alectinib administration as well‐tolerated maintenance therapy[5, 6]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.